When DNA repair genes are mutated it causes genomic instability which can lead to cancer. Hence, those who have DNA repair genes mutations are at higher risk of certain cancers (e.g., prostate, breast, ovarian, colorectal) than the general population. Further, these mutations often occur in reproductive cells so there is hereditary risk of mutations and cancer in family members of those who harbor DNA repair gene mutations.
Strand’s UroSeq® Hereditary DNA Repair Gene Panel testing includes includes BRCA1, BRCA2, ATM, CHEK2, HOXB13, PALB2 and RAD51D and the Lynch Syndrome genes MLH1, MSH2, MSH6, PMS2, and EPCAM. These are the genes that the National Comprehensive Cancer Network recommends be tested for those patients diagnosed with prostate cancer. The test can be completed with a saliva sample collected in the convenience of your home or your physician’s office. If your physician uses the know error® system your sample has already been collected at the time of your biopsy.
If you have additional questions about the UroSeq Hereditary DNA Repair Gene Panel please visit our FAQs for patients or email Strand’s client services department and include your question(s) in the message.
Who should be tested?
- Patients with a Gleason score of 8, 9 or 10
- Patients with metastatic prostate cancer
- Patients with a Gleason score of 6 or 7 AND
- A strong family history of prostate cancer (defined as: brother or father or multiple family members who were diagnosed with prostate cancer at less than 60 years of age or who died from prostate cancer), OR
- Ashkenazi Jewish ancestry, OR
- Three (3) cancers on same side of family (especially those diagnosed ≤50 years of age diagnosed with bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate, small bowel, or urothelial cancer)
To find out if Strand’s UroSeq® Hereditary DNA Repair Gene Panel is right for you please call 1-888-924-6779 and select option 2. Client service representatives are available Monday – Friday 8 am to 5 pm ET to assist you.
What are the clinical implications of pathogenic Hereditary DNA Repair gene mutation?
There are four main implications for pathogenic mutation:
- Patients are more likely to have aggressive disease and progress or recur more quickly
- Patients are at greater risk of additional primary cancers
- Patients may respond to PARP inhibitors
- Family member of patients with pathogenic mutations are at increased risk of cancer
If your UroSeq® test is positive for a gene mutation your physician and Strand Diagnostics will arrange for a complimentary consultation with a certified genetic counselor. During this consultation additional information will be provided and all of your questions will be addressed.